Sipuleucel-T approval (2010)
The FDA approved sipuleucel-T, sold as Provenge, for advanced prostate cancer. It was the first therapeutic cancer vaccine to reach the market. Its pivotal trial showed a median survival gain of 4.1 months, 25.8 months against 21.7.
Each dose had to be manufactured from the patient's own cells, which made the drug expensive and slow to deliver.
Dendreon, the maker, filed for bankruptcy in 2014. The episode became the standard cautionary tale about cancer vaccines with modest survival gains.
Galinpepimut-S is off-the-shelf and reports a 9.3-month median gain, so the questions facing it are about confirmation and durability rather than manufacturing.
